Cargando…

Low‐dose fenfluramine significantly reduces seizure frequency in Dravet syndrome: a prospective study of a new cohort of patients

BACKGROUND AND PURPOSE: Dravet syndrome (DS) is a severe, drug‐resistant epilepsy. Fenfluramine has been reported to have a long‐term clinically meaningful anticonvulsive effect in patients with DS. METHODS: This prospective, open‐label study assessed the safety and effectiveness of low‐dose fenflur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schoonjans, A., Paelinck, B. P., Marchau, F., Gunning, B., Gammaitoni, A., Galer, B. S., Lagae, L., Ceulemans, B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298030/ https://www.ncbi.nlm.nih.gov/pubmed/27790834 http://dx.doi.org/10.1111/ene.13195

Ejemplares similares

Fenfluramine significantly reduces day‐to‐day seizure burden by increasing number of seizure‐free days and time between seizures in patients with Dravet syndrome: A time‐to‐event analysis
por: Sullivan, Joseph, et al.
Publicado: (2021)

Fenfluramine: New Treatment for Seizures in Dravet Syndrome
por: Pierce, Joanna Garcia, et al.
Publicado: (2020)

Pharmacological Characterization of an Antisense Knockdown Zebrafish Model of Dravet Syndrome: Inhibition of Epileptic Seizures by the Serotonin Agonist Fenfluramine
por: Zhang, Yifan, et al.
Publicado: (2015)

Fenfluramine HCl (Fintepla(®)) provides long‐term clinically meaningful reduction in seizure frequency: Analysis of an ongoing open‐label extension study
por: Sullivan, Joseph, et al.
Publicado: (2020)

Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox–Gastaut syndrome: Interim analysis of an open‐label extension study
por: Knupp, Kelly G., et al.
Publicado: (2022)

Efficacy and Safety of Fenfluramine for the Treatment of Seizures Associated With Lennox-Gastaut Syndrome: A Randomized Clinical Trial
por: Knupp, Kelly G., et al.
Publicado: (2022)

Fenfluramine for Treatment-Resistant Seizures in Patients With Dravet Syndrome Receiving Stiripentol-Inclusive Regimens: A Randomized Clinical Trial
por: Nabbout, Rima, et al.
Publicado: (2020)

Efficacy of Fenfluramine and Norfenfluramine Enantiomers and Various Antiepileptic Drugs in a Zebrafish Model of Dravet Syndrome
por: Li, Jing, et al.
Publicado: (2021)

A review of fenfluramine for the treatment of Dravet syndrome patients
por: Simon, Kayla, et al.
Publicado: (2021)

Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes
por: Frampton, James E.
Publicado: (2023)

Correction to: Fenfluramine: A Review in Dravet and Lennox-Gastaut Syndromes
por: Frampton, James E.
Publicado: (2023)

An examination of the efficacy and safety of fenfluramine in adults, children, and adolescents with Dravet syndrome in a real‐world practice setting: A report from the Fenfluramine European Early Access Program
por: Guerrini, Renzo, et al.
Publicado: (2022)

Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: Analysis of an ongoing long‐term open‐label safety extension study
por: Lai, Wyman W., et al.
Publicado: (2020)

Fenfluramine: a plethora of mechanisms?
por: Sourbron, Jo, et al.
Publicado: (2023)

Fenfluramine in the successful treatment of super-refractory status epilepticus in a patient with Dravet syndrome
por: Millett, David, et al.
Publicado: (2021)

A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects
por: Boyd, Brooks, et al.
Publicado: (2019)

Fenfluramine for Treating Dravet Syndrome: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Wijnen, Ben, et al.
Publicado: (2022)

Dose-Ranging Effect of Adjunctive Oral Cannabidiol vs Placebo on Convulsive Seizure Frequency in Dravet Syndrome: A Randomized Clinical Trial
por: Miller, Ian, et al.
Publicado: (2020)

Effect of fenfluramine on convulsive seizures in CDKL5 deficiency disorder
por: Devinsky, Orrin, et al.
Publicado: (2021)

Pharmacological Analysis of the Anti-epileptic Mechanisms of Fenfluramine in scn1a Mutant Zebrafish
por: Sourbron, Jo, et al.
Publicado: (2017)

Reintroducing Fenfluramine as a Treatment for Seizures: Current Knowledge, Recommendations and Gaps in Understanding
por: Dini, Gianluca, et al.
Publicado: (2023)

Serotonergic modulation as a pharmacological modality in the treatment of Dravet syndrome
por: de Witte, Peter, et al.
Publicado: (2017)

Treatment of Focal-Onset Seizures in Children: Should This Be More Etiology-Driven?
por: Aeby, Alec, et al.
Publicado: (2022)

In vitro evaluation of fenfluramine and norfenfluramine as victims of drug interactions
por: Martin, Parthena, et al.
Publicado: (2022)

Perampanel Reduces Hyperthermia-Induced Seizures in Dravet Syndrome Mouse Model
por: Ho, Shih-Yin, et al.
Publicado: (2021)

Seizure reduction with fluoxetine in an adult woman with Dravet syndrome
por: Meador, Kimford J.
Publicado: (2014)

Effect of fenfluramine on seizures and comorbidities in SCN8A‐developmental and epileptic encephalopathy: A case series
por: Aledo‐Serrano, Ángel, et al.
Publicado: (2022)

Seizure control in a patient with Dravet syndrome and cystic fibrosis()
por: Schmalbach, Barbara, et al.
Publicado: (2013)

Dravet syndrome: A systematic literature review of the illness burden
por: Strzelczyk, Adam, et al.
Publicado: (2023)

Fenfluramine in the treatment of hypertensive patients with refractory obesity.
por: Scott, M. E., et al.
Publicado: (1975)

Improving Therapy of Pharmacoresistant Epilepsies: The Role of Fenfluramine
por: Dini, Gianluca, et al.
Publicado: (2022)

Drug repurposing for Dravet syndrome in scn1Lab (−/−) mutant zebrafish
por: Sourbron, Jo, et al.
Publicado: (2019)

A Practical Guide to the Treatment of Dravet Syndrome with Anti-Seizure Medication
por: Strzelczyk, Adam, et al.
Publicado: (2022)

In vitro evaluation suggests fenfluramine and norfenfluramine are unlikely to act as perpetrators of drug interactions
por: Martin, Parthena, et al.
Publicado: (2022)

Risk of valvular heart disease associated with use of fenfluramine
por: Hopkins, Paul N, et al.
Publicado: (2003)

Corrigendum: Improving therapy of pharmacoresistant epilepsies: The role of fenfluramine
por: Dini, Gianluca, et al.
Publicado: (2023)

Anesthetic considerations in Dravet syndrome
por: Macdonald‐Laurs, Emma, et al.
Publicado: (2022)

Chronic partial TrkB activation reduces seizures and mortality in a mouse model of Dravet syndrome
por: Gu, Feng, et al.
Publicado: (2022)

Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening
por: Griffin, Aliesha, et al.
Publicado: (2018)

Donepezil increases resistance to induced seizures in a mouse model of Dravet syndrome
por: Wong, Jennifer C., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_22ll1oi1l9lcu356d1i1shm8ug